News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights
-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 – -- $186 million in cash and investments at September 30, 2018 -- -- Received Orphan Drug Designation for CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Conference call today
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018
MOUNTAIN VIEW, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis -- -- Reveals Potential New Role for Chemokine Receptor 2 (CCR2) in the Treatment of Focal Segmental Glomerulosclerosis (FSGS) with First
View HTML
Toggle Summary ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
View HTML
Toggle Summary ChemoCentryx Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to
View HTML
Toggle Summary ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September: 20 th Annual Rodman & Renshaw Global Investment
View HTML
Toggle Summary ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Launch of clinical
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018
MOUNTAIN VIEW, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Corporate
View HTML